Is hepcidin a possible contributor to impaired iron mobilization and anaemia in hepatitis C patients treated with pegylated interferon alpha and ribavirin therapy? A pilot study

Not Applicable

Recruiting

• Conditions: Infection - Other infectious diseases; Hepatitis C; Anaemia; Blood - Anaemia; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12611001188921
• Lead Sponsor: Prof John Olynyk

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-11-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

We will prospectively study 30 consecutive patients with Hepatitis C infection that are being treated with interferon alpha and ribavirin at Fremantle hospital.

Exclusion Criteria

participation in other clinical trials.

Study & Design

• Study Type: Observational
• Study Design: Not specified